Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999-2006

N. Sathiakumar, E. Delzell, M. A. Morrisey, C. Falkson, M. Yong, V. Chia, Justin Blackburn, T. Arora, M. L. Kilgore

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Information on the impact of bone metastasis and skeletal-related events (SREs) on mortality among prostate cancer patients is limited. Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified men aged 65 years or older diagnosed with prostate cancer between July 1 1999 and December 31 2005 and followed to determine deaths through December 31 2006. We classified subjects as having bone metastasis and SREs as indicated by Medicare claims. Using Cox regression, we estimated mortality hazards ratios (HR) among men with bone metastasis with or without SRE, compared with men without bone metastasis. Among 126 978 men with prostate cancer (median follow-up, 3.3 years), 9746 (7.7%) had bone metastasis at prostate cancer diagnosis (1.7%) or during follow-up (5.9%). SREs occurred in 4296 (44%) men with bone metastasis. HRs for risk of death were 6.6 (95% CI=6.4-6.9) and 10.2 (95% CI=9.8-10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis. Bone metastasis was associated with mortality among prostate cancer patients. This association appeared to be stronger for bone metastasis plus SRE than for bone metastasis without SRE.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalProstate Cancer and Prostatic Diseases
Volume14
Issue number2
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Medicare
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Mortality
Population
Epidemiology
Databases

Keywords

  • bone metastasis
  • mortality
  • prostate cancer bone involvement
  • skeletal-related events

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Mortality following bone metastasis and skeletal-related events among men with prostate cancer : A population-based analysis of US Medicare beneficiaries, 1999-2006. / Sathiakumar, N.; Delzell, E.; Morrisey, M. A.; Falkson, C.; Yong, M.; Chia, V.; Blackburn, Justin; Arora, T.; Kilgore, M. L.

In: Prostate Cancer and Prostatic Diseases, Vol. 14, No. 2, 01.06.2011, p. 177-183.

Research output: Contribution to journalArticle

Sathiakumar, N. ; Delzell, E. ; Morrisey, M. A. ; Falkson, C. ; Yong, M. ; Chia, V. ; Blackburn, Justin ; Arora, T. ; Kilgore, M. L. / Mortality following bone metastasis and skeletal-related events among men with prostate cancer : A population-based analysis of US Medicare beneficiaries, 1999-2006. In: Prostate Cancer and Prostatic Diseases. 2011 ; Vol. 14, No. 2. pp. 177-183.
@article{c9cf69bb8c064ad5864a3aea968e5a89,
title = "Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999-2006",
abstract = "Information on the impact of bone metastasis and skeletal-related events (SREs) on mortality among prostate cancer patients is limited. Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified men aged 65 years or older diagnosed with prostate cancer between July 1 1999 and December 31 2005 and followed to determine deaths through December 31 2006. We classified subjects as having bone metastasis and SREs as indicated by Medicare claims. Using Cox regression, we estimated mortality hazards ratios (HR) among men with bone metastasis with or without SRE, compared with men without bone metastasis. Among 126 978 men with prostate cancer (median follow-up, 3.3 years), 9746 (7.7{\%}) had bone metastasis at prostate cancer diagnosis (1.7{\%}) or during follow-up (5.9{\%}). SREs occurred in 4296 (44{\%}) men with bone metastasis. HRs for risk of death were 6.6 (95{\%} CI=6.4-6.9) and 10.2 (95{\%} CI=9.8-10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis. Bone metastasis was associated with mortality among prostate cancer patients. This association appeared to be stronger for bone metastasis plus SRE than for bone metastasis without SRE.",
keywords = "bone metastasis, mortality, prostate cancer bone involvement, skeletal-related events",
author = "N. Sathiakumar and E. Delzell and Morrisey, {M. A.} and C. Falkson and M. Yong and V. Chia and Justin Blackburn and T. Arora and Kilgore, {M. L.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1038/pcan.2011.7",
language = "English (US)",
volume = "14",
pages = "177--183",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Mortality following bone metastasis and skeletal-related events among men with prostate cancer

T2 - A population-based analysis of US Medicare beneficiaries, 1999-2006

AU - Sathiakumar, N.

AU - Delzell, E.

AU - Morrisey, M. A.

AU - Falkson, C.

AU - Yong, M.

AU - Chia, V.

AU - Blackburn, Justin

AU - Arora, T.

AU - Kilgore, M. L.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Information on the impact of bone metastasis and skeletal-related events (SREs) on mortality among prostate cancer patients is limited. Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified men aged 65 years or older diagnosed with prostate cancer between July 1 1999 and December 31 2005 and followed to determine deaths through December 31 2006. We classified subjects as having bone metastasis and SREs as indicated by Medicare claims. Using Cox regression, we estimated mortality hazards ratios (HR) among men with bone metastasis with or without SRE, compared with men without bone metastasis. Among 126 978 men with prostate cancer (median follow-up, 3.3 years), 9746 (7.7%) had bone metastasis at prostate cancer diagnosis (1.7%) or during follow-up (5.9%). SREs occurred in 4296 (44%) men with bone metastasis. HRs for risk of death were 6.6 (95% CI=6.4-6.9) and 10.2 (95% CI=9.8-10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis. Bone metastasis was associated with mortality among prostate cancer patients. This association appeared to be stronger for bone metastasis plus SRE than for bone metastasis without SRE.

AB - Information on the impact of bone metastasis and skeletal-related events (SREs) on mortality among prostate cancer patients is limited. Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified men aged 65 years or older diagnosed with prostate cancer between July 1 1999 and December 31 2005 and followed to determine deaths through December 31 2006. We classified subjects as having bone metastasis and SREs as indicated by Medicare claims. Using Cox regression, we estimated mortality hazards ratios (HR) among men with bone metastasis with or without SRE, compared with men without bone metastasis. Among 126 978 men with prostate cancer (median follow-up, 3.3 years), 9746 (7.7%) had bone metastasis at prostate cancer diagnosis (1.7%) or during follow-up (5.9%). SREs occurred in 4296 (44%) men with bone metastasis. HRs for risk of death were 6.6 (95% CI=6.4-6.9) and 10.2 (95% CI=9.8-10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis. Bone metastasis was associated with mortality among prostate cancer patients. This association appeared to be stronger for bone metastasis plus SRE than for bone metastasis without SRE.

KW - bone metastasis

KW - mortality

KW - prostate cancer bone involvement

KW - skeletal-related events

UR - http://www.scopus.com/inward/record.url?scp=79956083610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956083610&partnerID=8YFLogxK

U2 - 10.1038/pcan.2011.7

DO - 10.1038/pcan.2011.7

M3 - Article

C2 - 21403668

AN - SCOPUS:79956083610

VL - 14

SP - 177

EP - 183

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -